<DOC>
	<DOCNO>NCT00527072</DOCNO>
	<brief_summary>The purpose study test safety effectiveness infliximab patient plaque psoriasis receive drug etanercept treatment plaque psoriasis least four month , without enough improvement psoriasis symptom .</brief_summary>
	<brief_title>PSUNRISE - Prospective Study Using Remicade Psoriasis Patients With Inadequate Response Etanercept</brief_title>
	<detailed_description>The common form psoriasis plaque-type psoriasis , characterize recurrent flaring thicken , red , scaly patch skin . Although psoriasis usually life threatening , physical discomfort combine potential psychological effect disease may interfere everyday activity negatively impact individual 's quality life . Many therapy available psoriasis ; however , limited effectiveness significant toxicity . Infliximab antibody make laboratory . Antibodies proteins fight substance body may cause infection disease . A substance call `` tumor necrosis factor '' ( TNF ) naturally occur body . TNF related itchy patch skin ( plaque ) psoriasis . Infliximab stop TNF work . Other study show stop TNF may reduce plaque . To address unmet medical need effective chronic therapy , TNFalpha blocker recently use treat patient moderate severe plaque psoriasis . Etanercept also work stop TNF , different way infliximab . This multi-center , open-label study design test whether patient plaque psoriasis respond well etanercept treatment may benefit treatment infliximab . Key effectiveness measurement include time onset symptom improvement health-related quality life . Safety assess throughout study . Two week last dose etanercept , eligible patient receive open-label 5 mg/kg infliximab infusion Weeks 0 , 2 , 6 , 14 , 22 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Have plaque psoriasis despite least 4 month treatment etanercept per current product labeling Have psoriatic target lesion PGA score great 1 ( minimal ) screen If receive methotrexate screening , must receive methotrexate least 3 month stable dose &lt; = 25 mg/week least 4 week prior screen If receive cyclosporine screening , must receive cyclosporine stable dose &lt; = 5 mg/kg daily least 4 week prior screen . Have already receive infliximab adalimumab Have show previous immediate hypersensitivity response , include anaphylaxis , immunoglobulin product Have history latent active granulomatous infection , include tuberculosis , histoplasmosis , coccidioidomycosis , prior screen Have concomitant diagnosis history Congestive Heart Failure Are pregnant , nursing , plan pregnancy Have use systemic corticosteroid within 4 week prior screen Have use topical corticosteroid initiate treatment topical therapy could affect psoriasis Psoriasis Area Severity Index ( PASI ) evaluation ( e.g. , tar , anthralin , calcipotriene , tazarotene , methoxsalen ) within 2 week prior screen Have use new systemic agents/treatments , methotrexate , affect psoriasis include , limited , immunosuppressant and/or psoralen plus ultraviolet A light ( PUVA ) within 4 week prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>plaque psoriasis</keyword>
	<keyword>psoriasis</keyword>
	<keyword>infliximab</keyword>
	<keyword>remicade</keyword>
	<keyword>etanercept</keyword>
	<keyword>enbrel</keyword>
	<keyword>psunrise</keyword>
	<keyword>C0168Z04</keyword>
</DOC>